KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $943.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $943.4 million for Q4 2025, up 5.12% from a year ago — trailing twelve months through Dec 2025 was $3.7 billion (up 11.69% YoY), and the annual figure for FY2025 was $4.7 billion, up 40.14%.
  • Operating Expenses for Q4 2025 was $943.4 million at Jazz Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Operating Expenses for JAZZ hit a ceiling of $1.7 billion in Q2 2025 and a floor of $445.5 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $835.8 million (2024), compared with a mean of $894.8 million.
  • Peak annual rise in Operating Expenses hit 125.47% in 2021, while the deepest fall reached 38.51% in 2021.
  • Jazz Pharmaceuticals' Operating Expenses stood at $847.4 million in 2021, then surged by 45.81% to $1.2 billion in 2022, then decreased by 28.01% to $889.4 million in 2023, then increased by 0.9% to $897.4 million in 2024, then grew by 5.12% to $943.4 million in 2025.
  • The last three reported values for Operating Expenses were $943.4 million (Q4 2025), $1.1 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.